Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients

Human Gene Therapy Clinical Development

Volumn 28, Issue 3, 2017, Pages 136-144

  Uchida, Naoya ^a   Fujita, Atsushi ^a   Hsieh, Matthew M ^a   Bonifacino, Aylin C ^a   Krouse, Allen E ^a   Metzger, Mark E ^a   Donahue, Robert E ^a   Tisdale, John F ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

gene therapy; hematopoietic stem cells; sickle cell disease

Indexed keywords

CD34 ANTIGEN; HYDROXYUREA; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD CELL; BONE MARROW; BONE MARROW CELL; GENE TARGETING; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SICKLE CELL ANEMIA; STEM CELL GENE THERAPY; VIRAL GENE THERAPY; ANIMAL; BLOOD; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE THERAPY; GENETICS; METABOLISM; MOUSE; PRIMARY CELL CULTURE; PROCEDURES;

ANEMIA, SICKLE CELL; ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; CELLS, CULTURED; GENETIC THERAPY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROXYUREA; MACACA MULATTA; MICE; PRIMARY CELL CULTURE;

EID: 85041095928     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2017.029     Document Type: Article

References (44)

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
2. Fitzhugh CD, Hsieh MM, Allen D, et al. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS One 2015; 10:e0141706.
3. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361: 2309-2317.
4. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014;312: 48-56.
5. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-376.
6. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-322.
7. Zou J, Mali P, Huang X, Dowey SN, Cheng L. Sitespecific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011;118:4599-4608.
8. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360: 447-458.
9. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-2413.
10. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-256.
11. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-409.
12. Schwarzwaelder K, Howe SJ, Schmidt M, et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007;117:2241-2249.
13. Smith EC, Orkin SH. Hemoglobin genetics: recent contributions of GWAS and gene editing. Human molecular genetics 2016;25:R99-r105.
14. Urbinati F, Hargrove PW, Geiger S, et al. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol 2015;43:346-351.
15. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 2015;125: 2597-2604.
16. Hoban MD, Lumaquin D, Kuo CY, et al. CRISPR/ Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells. Mol Ther 2016;24:1561-1569.
17. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-1923.
18. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy 2009;11:464-471.
19. Uchida N, Hargrove PW, Lap CJ, et al. Highefficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector. Mol Ther 2012;20:1882-1892.
20. Uchida N, Washington KN, Hayakawa J, et al. Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol 2009;83:9854-9862.
21. Uchida N, Bonifacino A, Krouse AE, et al. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. Exp Hematol 2011;39:795-805.
22. Uchida N, Hsieh MM, Washington KN, Tisdale JF. Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid. Exp Hematol 2013;41:779-788 e771.
23. Uchida N, Evans ME, Hsieh MM, et al. Integrationspecific in vitro evaluation of lentivirally transduced rhesus CD34(+) cells correlates with in vivo vector copy number. Mol Ther Nucleic Acids 2013;2:e122.
24. Uchida N, Hanawa H, Dan K, Inokuchi K, Shimada T. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. J Nippon Med Sch 2009;76:134-147.
25. Fujita A, Uchida N, Haro-Mora JJ, Winkler T, Tisdale J. beta-globin-expressing definitive erythroid progenitor cells generated from embryonic and induced pluripotent stem cell-derived sacs. Stem Cells 2016.
26. Uchida N, Haro-Mora JJ, Fujita A, et al. Efficient generation of b-globin-expressing erythroid cells using stromal cell-derived induced pluripotent stem cells from patients with sickle cell disease. Stem Cells 2016:n/a-n/a.
27. Hematti P, Tuchman S, Larochelle A, Metzger ME, Donahue RE, Tisdale JF. Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. Stem Cells 2004;22: 1062-1069.
28. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000;406:82-86.
29. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001;294:2368-2371.
30. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419.
31. Evans ME, Kumkhaek C, Hsieh MM, Donahue RE, Tisdale JF, Uchida N. TRIM5alpha variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo. Mol Ther 2014;22:348-358.
32. Luck L, Zeng L, Hiti AL, Weinberg KI, Malik P. Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells. Exp Hematol 2004;32:483-493.
33. Dedeepiya VD, Rao YY, Jayakrishnan GA, et al. Index of CD34+ Cells and Mononuclear cells in the bone marrow of spinal cord injury patients of different age groups: a comparative analysis. Bone Marrow Res 2012;2012:787414.
34. Kanter J, Walters MC, Hsieh MM, et al. Interim results from a Phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. Blood 2016;128:1176-1176.
35. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe betathalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 2012;20:230-238.
36. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a patient with sickle cell disease. N Engl J Med 2017;376:848-855.
37. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001;27:689-692.
38. Lane TA. Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era. Transfusion 1996;36:585-589.
39. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet 1998;351:959.
40. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001;97:3313-3314.
41. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730.
42. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-1318.
43. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112:990-998.
44. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-1262.